Company Files for Approval of New Pustular Psoriasis Rx

Imsidolimab is a monoclonal antibody that inhibits interleukin-36 receptor signaling and is administered intravenously.
Medscape Medical News

source https://www.medscape.com/viewarticle/company-files-approval-biologic-treating-generalized-2026a100060x?src=rss